euro adhoc: Intercell AG / Restructuring & Recapitalisations / Intercell AG: Over-allotment option fully exercised

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

07.07.2006

Intercell announced today that Merrill Lynch International, the
underwriter of its recent public offering of common shares, has
exercised in full the over-allotment option which was granted by the
selling shareholders. The over-allotment comprised of 1,142,848
existing shares of common stock which were placed at the offer price
of EUR 12.36. Following the exercise of the over-allotment option,
the gross proceeds from the combined primary and secondary offering
totaled EUR 110.6 million.

Intercell’s major shareholders following the exercise of the
over-allotment option are: Apax Partners (11.6 %), Temasek Holdings
(8.1 %), Novartis (6.1 %), TVM Capital (6.0 %) and Kapital & Wert
Group (5.7 %). 1.3 % of the shares issued are held by Intercell as
treasury stock and 1.8 % are held by the management. The current
free float is 59.3 %.

Intercell has a total of 39,531,897 issued shares of common stock,
which includes 518,389 shares of treasury stock.

Not for distribution in the United States, Canada and Japan This
press release does not constitute an offer to sell or the
solicitation of an offer to purchase the shares of Intercell AG. The
shares offered in connection with the public offering in Austria have
already been placed. The information contained herein is not for
publication or distribution in the United States, Canada, Japan or
Australia. This press release is not an offer of securities for sale
in the United States. The securities referred to herein have not been
and will not be registered under the U.S. Securities Act of 1933, as
amended (the Securities Act), and may not be offered or sold in the
United States absent registration under that Securities Act or an
available exemption from it. Any offering of securities to be made in
the United States will be made by means of an offering circular that
may be obtained from Intercell AG and will contain detailed
information about the company and management, as well as financial
statements. This communication expressly or implicitly contains
certain forward-looking statements concerning Intercell AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
This press release is directed at and/or for distribution in the UK
only to (i) persons who have professional experience in matters
relating to investments falling within article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
"Order") or (ii) high net worth entities falling within article
49(2)(a) to (d) of the Order (all such persons being together
referred to as "relevant persons"). This press release is directed
only at relevant persons. Any person who is not a relevant person
should not act or rely on this press release or any of its contents.
Any investment or investment activity to which this press release
relates is available only to relevant persons and will be engaged in
only with relevant persons.

end of announcement euro adhoc 07.07.2006 06:55:44
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market